ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
Kernal Bio, a Cambridge, MA-based TechBio therapeutics company, received an undisclosed investment from the Institute for Follicular Lymphoma Innovation (IFLI). The company plans to use the funds to accelerate development of KR-402, its new mRNA-encoded CAR-T candidate for B-cell malignancies and autoimmune diseases.
Tap to vote and see what everyone thinks.
Summary by ByteBrief